Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2022-10-01
2024-03-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts
NCT05781841
Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris
NCT05409365
Gardasil Versus Cervarix in the Treatment of Warts
NCT05383625
Evaluation of Combined Treatment With Er:YAG & Nd:YAG Lasers for the Treatment of Recalcitrant Warts
NCT05768893
Prevalence of HPV-associated Eye Infection and Cytokine Levels in Tears From Patients Diagnosed With Pterygium
NCT04117386
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
endoplasmic reticulum Aminopeptidase 1 and 2
endoplasmic reticulum aminopeptidase1 and 2 serum levels determination via ELISA
endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA
endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients on systemic steroids or other immunosuppressive treatments
* Immunocompromised individuals
* Patients suffering from chronic systemic diseases
* Pregnant women
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
karem Taha ibrahim khalil
assistant professor of dermatology, venereology and andrology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ihab Y. Abdallah, MD
Role: STUDY_CHAIR
Professor of Dermatology, Venereology and Andrology, Faculty of Medicine, Benha University
Nehad A.Fouad, MD
Role: STUDY_DIRECTOR
Professor of Microbiology and Immunology, Faculty of Medicine, Benha University
Ola S Ebrahim, MBBCh
Role: PRINCIPAL_INVESTIGATOR
Benha University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
faculty of medicine Benha University
Banhā, Qalyubia Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Serum ERAP1 and 2 in warts
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.